Results 51 to 60 of about 27,891 (313)

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

Nature Medicine, 2022
The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity,
W. Garvey, R. Batterham, M. Bhatta, S. Buscemi, L. Christensen, J. Frias, E. Jódar, K. Kandler, G. Rigas, T. Wadden, S. Wharton   +10 more
semanticscholar   +1 more source

Once-Weekly Semaglutide in Adolescents with Obesity.

New England Journal of Medicine, 2022
BACKGROUND A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking. METHODS In this double-blind, parallel-group,
D. Weghuber, T. Barrett, M. Barrientos-Pérez, I. Gies, Dan Hesse, O. Jeppesen, A. Kelly, L. Mastrandrea, R. Sørrig, S. Arslanian   +9 more
semanticscholar   +1 more source

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases [PDF]

, 2016
Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new ...
Holscher, Christian, Li, Lin, Li, Yanwei
core   +1 more source

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi, Mohanad A. Alkuwaiti, Yazeed B. Alaql, Ahmed K. Alsaif, Ahmed A. Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A. Alnaaim, Sajjad M. AlHaddad, Ahmed Y. Azzam   +9 more
wiley   +1 more source

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. [PDF]

, 2017
Importance: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection.
Davies, Melanie, Hansen, Oluf K.H., Hartoft-Nielsen, Marie-Louise, Jabbour, Serge, Pieber, Thomas R., Rosenstock, Julio   +5 more
core   +1 more source

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2022
Importance Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like peptide-1 analogues available for weight management. Objective To compare the efficacy and adverse event profiles of once-weekly subcutaneous semaglutide, 2.4 mg, vs
D. Rubino, F. Greenway, U. Khalid, P. O'Neil, J. Rosenstock, R. Sørrig, T. Wadden, Alicja Wizert, W. Garvey, Carlos Arauz-Pacheco, K. Cannon, H. Downey, David Fitz-Patrick, Jeffrey G. Geohas, Gregg Gerety, J. Gilbert, P. Hollander, Eric Klein, Karen L. Laufer, Philip O'donnell, P. Rosenblit, Phillip Toth   +21 more
semanticscholar   +1 more source

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, EarlyView.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2021
Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown.
D. Rubino, Niclas Abrahamsson, M. Davies, Dan Hesse, F. Greenway, Camilla Jensen, I. Lingvay, Ofri Mosenzon, J. Rosenstock, M. Rubio, G. Rudofsky, S. Tadayon, T. Wadden, D. Dicker   +13 more
semanticscholar   +1 more source

An Implantable Optogenetics‐Engineered Hydrogel for Amelioration of Rheumatoid Arthritis through Light‐Controlled Metabolic Reprogramming of Synovial Macrophages

Advanced Science, EarlyView.
An implantable hydrogel is designed to enable in situ and on‐demand secretion of GLP‐1 in synovium through blue light irradiation to activate GLP‐1R/HK2/VDAC1 pathway for upregulating tricarboxylic acid cycle and oxidative phosphorylation in macrophage, facilitating tissue repair and bone erosion recovery.
Dahai Hu, Yaru Sun, Qi Lu, Yi Zhang, Jieruo Li, Huige Hou, Huajun Wang, Hui Tang, Yunsong Zhang, Xiaofei Zheng, Qingsong Mei   +10 more
wiley   +1 more source

Effects of pH and Salts on the Aggregation State of Semaglutide and Membrane Filtration Performance

Separations
The hydrophobic region of semaglutide makes it prone to aggregation in aqueous solution, which leads to serious interception in microfiltration. The influences of pH and low concentrations of salts (NaCl, CH3COONa, Na2SO4 and (NH4)2SO4) on the particle ...
Lei Duan, Yu Yang, Hao Wu, Xuehuan Ding, Min Jiang   +4 more
doaj   +1 more source